SPAG11B, a potential biomarker for rheumatoid arthritis: A two-sample bidirectional mendelian randomization analysis

Kun‐Ju Lin, Qi Lin, Weifeng Lv, Yao Li, Rong SuResearch Square 2025 · DOI

Introduction

Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune condition characterized by persistent joint inflammation and progressive structural damage. Despite its increasing prevalence, the precise pathogenesis of RA remains partially understood, and existing therapeutic options often fail to achieve complete remission for all patients.

Identifying reliable biomarkers is critical for early diagnosis and the development of targeted therapies. While plasma proteins are essential regulators of biological pathways, traditional observational studies often struggle to distinguish whether a protein's presence is a cause of the disease or a consequence of it—a phenomenon known as reverse causality. This study addresses this gap by utilizing Mendelian randomization (MR) to identify plasma proteins with a genetically supported causal relationship with RA.

Methodology

To overcome the limitations of observational research, the authors employed a Two-Sample Bidirectional Mendelian Randomization (MR) approach. MR uses genetic variants, specifically Single Nucleotide Polymorphisms (SNPs), as "instrumental variables" to mimic the structure of a randomized controlled trial. Because these variants are randomly assigned at birth, they are not influenced by environmental factors or the disease process itself, allowing for more robust causal inferences.

Study workflow for identifying causal plasma proteins in rheumatoid arthritis.

Data Sources

The study integrated large-scale genomic and proteomic datasets:

  • Proteomic Exposure: Data from the deCODE database, involving protein quantitative trait loci (pQTL) for 4,907 plasma proteins from over 35,000 individuals.
  • Primary Outcome: RA genome-wide association data from the FinnGen database (12,555 cases).
  • Validation Cohorts: Findings were cross-referenced against the IEU OpenGWAS and UK Biobank datasets to ensure reproducibility.

Statistical Analysis

The primary analysis utilized the Inverse Variance Weighting (IVW) method. To ensure the integrity of the results and account for potential "pleiotropy" (where a single gene affects multiple unrelated traits), the researchers performed sensitivity analyses using MR-Egger and Weighted Median methods. Finally, a reverse MR analysis was conducted to determine if the presence of RA itself influences the levels of the identified proteins.

Key Results

The Identification of SPAG11B

From the initial screen of nearly 5,000 proteins, two candidates—SPAG11B (Sperm Associated Antigen 11B) and DEFB135—showed significant protective associations with RA. However, only SPAG11B successfully passed the external validation phase across multiple cohorts.

  • Primary Analysis (FinnGen): Elevated plasma levels of SPAG11B were associated with a 51% reduction in the risk of RA (OR = 0.49, 95% CI = 0.40-0.61, p = 1.19 × 10⁻¹⁰).
  • Validation: The protective effect was replicated in the IEU cohort (OR = 0.26) and the UK Biobank, confirming the protein's robust association with reduced disease risk.

Bidirectional Causality

One of the study's most significant findings was the bidirectional nature of the relationship. While higher SPAG11B levels protect against RA, the reverse MR analysis revealed that the presence of RA causally reduces plasma levels of SPAG11B (OR = 0.93, p = 0.004). This suggests a feedback loop where the disease actively depletes a protective factor, potentially accelerating progression.

Discussion and Biological Plausibility

Though SPAG11B is traditionally associated with reproductive biology, emerging evidence supports its role in inflammatory regulation. The authors note that SPAG11B exhibits trypsin-like inhibitory activity. In animal models, similar proteins have been shown to inhibit joint edema and suppress the release of pro-inflammatory cytokines such as IL-6. This provides a plausible mechanical explanation for why individuals with genetically higher levels of SPAG11B are less susceptible to the chronic inflammation seen in RA.

In contrast, the protein DEFB135, which initially appeared promising, failed to replicate in validation cohorts. This underscores the necessity of the study's multi-cohort design in filtering out false positives that often plague smaller genetic studies.

Conclusion

This study identifies SPAG11B as a high-priority candidate for future RA research. Its consistent protective effect and the discovery of reverse causality suggest it could serve as both a diagnostic biomarker and a potential therapeutic target.

Future work is required to validate these findings in non-European populations and to conduct "wet lab" experiments. Specifically, functional studies using RA cell lines and animal models are needed to map the exact molecular pathways through which SPAG11B exerts its anti-inflammatory effects in joint tissue.

Summary updated

Abstract

<title>Abstract</title> <bold>Background: </bold>The incidence of rheumatoid arthritis (RA) is rising. However, its pathogenesis has not been fully understood, and the current therapeutic regimens are still limited. The aim of this study was to investigate the causal effect of plasma proteins on RA using Mendelian randomization (MR) analysis. <bold>Methods: </bold>We performed MR analysis with 4907 plasma protein genetic associations used for exposure and RA genome-wide association data used as outcomes. The method was dominated by Inverse Variance Weighting, in addition to MR-Egger and Weighted Median. Meanwhile, further external validation and reverse MR analysis were conducted to systematically assess the causal relationship between plasma proteins and RA. <bold>Result: </bold>Preliminary MR analysis identified two proteins (SPAG11B and DEFB135) associated with RA, and elevated plasma levels of both proteins would reduce the risk of RA (for SPAG11B, OR =0.49, 95% CI =0.40-0.61, <italic>p</italic> =1.19×10<sup>-10</sup>; for DEFB135, OR =0.28, 95% CI =0.15-0.52, <italic>p</italic> =4.51×10<sup>-5</sup>, using the IVW method). In the external validation phase, the results were reproducible for SPAG11B, but not for DEFB135. Reverse MR analysis pointed out that RA exhibited reverse causality for plasma levels of SPAG11B (OR=0.93, 95% CI=0.89-0.98, <italic>p</italic>=0.004), but not for DEFB135 (<italic>p</italic>=0.93). <bold>Conclusion: </bold>The results of MR analysis in this study supported that SPAG11B as a novel biomarker for RA was worthy of further investigation.
BibTeX
@inproceedings{lin2025spag,
  author = {Kun‐Ju Lin and Qi Lin and Weifeng Lv and Yao Li and Rong Su},
  title = {{SPAG11B, a potential biomarker for rheumatoid arthritis: A two-sample bidirectional mendelian randomization analysis}},
  booktitle = {Research Square},
  year = {2025},
  doi = {10.21203/rs.3.rs-6248365/v1},
}
Figure